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Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary adenocarcinoma, a transmissible lung cancer in sheep. Previous
experiments in differentiated murine tissue culture cell lines suggested that the disease specificity of JSRV for secretory lung epithelial cells (type
II pneumocytes an Clara cells) reflects transcriptional specificity of the viral long terminal repeat (LTR) for these cells. To test this in vivo,
transgenic mice carrying the bacterial beta-galactosidase (β-Gal) gene driven by the JSRV LTR were generated. Two transgenic lines showed β-
Gal expression in the lungs but not other tissues of F1 animals, although transgene silencing in subsequent generations was a major problem. The
cells expressing the transgene were identified by two- and three-color immunofluorescence for marker proteins of type II pneumocytes (surfactant
protein C [SPC]) and Clara cells (CC10) as well as for a T7 gene 10 epitope present in the β-Gal reporter. F1 animals from both lines showed
transgene expression in type II pneumocytes, but somewhat surprisingly not in Clara cells. Expression was not detected in bronchiolo-alveolar
stem cells (BASCs) either. These results indicate that the JSRV LTR is specifically active in type II pneumocytes in the mouse lung, which is
consistent with the fact that JSRV-induced OPA tumors in sheep largely have phenotypic markers of type II pneumocytes.
© 2007 Elsevier Inc. All rights reserved.Keywords: Jaagsiekte sheep retrovirus; Long terminal repeat; Transgenic mouse; Type II pneumocyte; Clara cell; BASC cell; Lung cancerIntroduction
The disease jaagsiekte is an acute and contagious respiratory
ailment in sheep and goats, predominantly found in Europe,
Africa and Latin America (Palmarini et al., 1997). Afflicted
animals exude foamy white fluid from their nose, ultimately
succumbing to pulmonary failure. Jaagsiekte, now termed ovine
pulmonary adenocarcinoma (OPA), is manifested by multifocal
tumors of secretory epithelial cells (type II pneumocytes and/or
Clara cells); excess secretory products from the tumor cells
comprise the nasal fluids typical of the disease. Type II
pneumocytes are located in the alveoli, where they secrete
surfactant necessary for maintaining hydration and gas perme-
ability of the alveoli. Clara cells are located in the bronchioles,
where they secrete products involved in the metabolism of⁎ Corresponding author. Fax: +1 949 824 4023.
E-mail address: hyfan@uci.edu (H. Fan).
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doi:10.1016/j.virol.2007.10.035foreign agents (Widdicombe and Pack, 1982). The causative
agent of OPA is an exogenous betaretrovirus, jaagsiekte sheep
retrovirus (JSRV) (Palmarini et al., 1999a; Holland et al., 1999).
JSRV is unique in that its envelope protein functions as an
oncogene that can transform cells in culture (Maeda et al., 2001;
Pannell et al., 2000; Allen et al., 2002) and in vivo (Wootton
et al., 2005; Caporale et al., 2006; Dakessian et al., 2007).
Another unusual feature of JSRV infection is that the virus
displays unusually strong tissue specificity in vivo for
expression in lung epithelial cells. In contrast to many other
oncogenic retroviruses (e.g. murine leukemia viruses (Fan,
1997) where productive infection is systemic, even end-stage
sheep with OPA largely show expression of viral proteins only
in the tumor cells (Palmarini et al., 1996). On the other hand,
evidence for viral infection in hematopoietic cells (by nested
PCR) can be found even at relatively early times after infection
(Holland et al., 1999); however these cells apparently do not
express the virus. Two possible mechanisms could affect the in
vivo tissue specificity of JSRV. First, the tissue distribution of
Fig. 1. The JSRV LTR-lacZ transgene. (A) Organization of the transgene is
shown. The JSRV Long Terminal Repeat (comprised of U3, R, and U5) drives
expression of the T7 epitope-tagged lacZ gene. The transcriptional start site is
denoted by the arrow. (B) The JSRV LTR-lacZ transgene was tested for activity
by transient transfection into murine Type 2 pneumocytes (MLE-15) and murine
fibroblasts (NIH-3T3). β-Gal activity was measured with a luminescent
substrate to the enzyme. Control expression plasmids included pCMV-LacZ
(β-Gal driven by the human cytomegalovirus immediate early promoter), and
pcDNA3.1 (CMV promoter, but no LacZ gene). β-Gal activities are shown with
standard errors of the mean.
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receptor is specifically expressed in lung epithelial cells —
similar to the restriction of HIV-1 infection to CD4- (and CCR5-
or CXCR4-) bearing cells in humans (Moore, 1997). However,
the JSRV receptor (hyaluronidase 2 [hyal2]) has been identified
(Rai et al., 2001), and it is distributed broadly among different
cell types. This is consistent with the facts that JSRV viral DNA
can be found in vivo in non-lung epithelial cells (Palmarini
et al., 1996), and that all ovine cell lines tested could support
JSRV replication in vitro at some level (Palmarini et al., 1999b).
Thus, in vivo lung specificity for JSRV infection cannot be
explained by the distribution of the receptor. This supports the
second mechanism, transcriptional specificity of the JSRV long
terminal repeat (LTR).
Retroviral LTRs carry the viral transcriptional signals in their
U3 regions, including the basal promoter (e.g. TATA element) as
well as upstream enhancer elements that bind cellular transcrip-
tion factors (Fan, 1997). For some retroviruses, the LTR en-
hancers show cell type specificity— e.g. the preferential activity
of the Moloney murine leukemia virus (M-MuLV) LTR in
T-lymphoid cells. This specificity is associated with the ability of
M-MuLV to induce T-lymphomas, resulting from preferential
insertional activation of cellular proto-oncogenes in T-lymphoid
cells (Chatis et al., 1984; Li et al., 1987; Lenz et al., 1984). For
most retroviruses, the transcriptional specificities of the LTRs
are not absolute. Even though the M-MuLV LTR has transcrip-
tional preference for T-lymphoid cells, it clearly functions in
other cell types since in vivo productive infection is observed in
non-T-lymphoid cells, including other hematopoietic cells and
non-hematopoietic cells (Davis et al., 1987). In contrast, the
JSRV LTR would have to show very strong lung cell specificity
if this were the explanation for the in vivo tissue specificity of
JSRV, since expression of viral proteins is largely only observed
in tumor cells in the lung.
We previously studied the transcriptional specificity of the
JSRV LTR in transient transfection assays (Palmarini et al.,
2000; McGee-Estrada et al., 2002, 2005). A reporter plasmid
consisting of the JSRV LTR driving the firefly luciferase gene
was tested in a variety of murine cell lines derived from different
cell types. With the exception of two lung epithelial-derived cell
lines (MLE-15 and mtCC1-2), the other cell lines showed little
activity of the JSRV LTR-luc reporter. MLE-15, which showed
the highest reporter activity, was derived from a tumor of type II
pneumocytes arising in a mouse containing a transgene con-
sisting of SV40 Large TAntigen driven by the surfactant protein
C (SPC) promoter (Wikenheiser et al., 1993). mtCC1-2 showed
significant but lower JSRV LTR activity, and was similarly
derived from a Clara cell tumor from a mouse containing an
SV40 Large TAntigen—Clara cell protein 10 (CC10) promoter
transgene (Magdaleno et al., 1997). These results were
consistent with the fact that most OPA tumors consist
predominantly of cells with properties of type II pneumocytes,
but they often also contain cells with Clara cell properties (Platt
et al., 2002). They also support the hypothesis that the in vivo
tissue specificity of JSRV is determined transcriptionally by the
LTR. Indeed, the JSRV LTR contains transcription factor
binding motifs known to be important for type II pneumocyte-specific genes, including HNF-3β and C/EBPα (McGee-Estrada
et al., 2002). Deletion or mutation of these sites strongly reduced
activity of the JSRV LTR in MLE-15 cells (McGee-Estrada and
Fan, 2006).
In these experiments, we further investigated the tissue spec-
ificity of the JSRV LTR by generating transgenic mice carrying
an LTR driving an epitope-tagged bacterial β-galactosidase
gene. This allowed us to investigate the activity of the LTR in
normal lung cells, and test if the specificity was that predicted by
the transient transfection assays in cell lines. Experiments with
other retroviral LTRs indicate that transgenic mice may provide
more biologically relevant read-outs compared to transient
transfection assays. Ross, Dudley and co-workers found that
transgenic mice carrying mutant murine mammary tumor virus
(MMTV) LTRs showed effects on hormone responsiveness,
while the same constructs in transient transfection assays did not
(Bramblett et al., 1995; Ross et al., 1990).
Studies of JSRV LTR expression in transgenic mice would
not only allow identification of target cells for infection, but they
might provide insights into target cells for oncogenic transfor-
mation. In particular, JSRV could be transforming differentiated
type II pneumocytes and/or Clara cells, or it could actually be
transforming stem cells. The fact that many OPA tumors are of
mixed phenotype (predominantly type II- derived cells, but with
varying proportions of Clara-derived cells (Platt et al., 2002)
would be consistent with tumorigenesis of a stem cell. Recently,
a stem cell population has been identified in the lung that can
differentiate into both type II pneumocytes and Clara cells (Kim
et al., 2005). These cells, bronchioloalveolar stem cells
(BASCs), are found in the transitional zone between the
bronchioles and the alveoli — the bronchiolo-alveolar ductal
Table 1
Transgene expression in different lines
Transgenic Line gender founder F1 F2 F3
A m + + − n/a
B m − − n/a n/a
C m − − n/a n/a
D m − − n/a n/a
E m − − n/a n/a
F m − − n/a n/a
G m + + + n/a
H m − − n/a n/a
I m + − n/a n/a
J f − − n/a n/a
K f − − n/a n/a
The transgenic lines obtained are shown, and the sexes of the founders are
indicated. All founders were positive for transgene DNA as measured by PCR,
and results for transgenic F1, F2 and F3 animals are shown. Expression was
determined by sacrificing animals and performing X-gal stains on frozen sections
from lung, spleen, liver and kidney. Only the lungs showed expression. +,
expression in one or more transgenic animals (for F1–F3 generations;
backcrossing to C57Bl6 mice). −, no transgene expression observed in at least
four F1mice tested. If F1 litters were negative by this criterion, theywere not bred
to subsequent generations. n/a, not applicable.
400 R.M. Dakessian, H. Fan / Virology 372 (2008) 398–408junction (BADJ). BASC cells are positive for both type II
pneumocyte and Clara cell-specific proteins (SPC and CC10
respectively). Expression of the JSRV LTR transgene in BASC
cells would support the idea that equivalent cells in sheep being
targets for JSRV tumorigenesis.Fig. 2. Transgene expression state in the A line. A transgenic F1 animal from the A lin
liver (C), and kidney (D). Positive conversion of the X-gal substrate (dark blue stainin
The bar in this and other figures represents 30 μm.Results
Generation of LTR-lacZ transgenic mice
To study the cell type specificity of the JSRV LTR, a reporter
construct (pJS21-lacZ) was generated in which the bacterial
beta-galactosidase (lacZ) gene was cloned downstream of the
entire 5′ JSRV LTR (Fig. 1A). The version of the lacZ gene
used also contained an inserted epitope from the bacteriophage
T7 gene 10 protein that would allow for detection with a
monoclonal antibody (Lindner et al., 1997). The fidelity of the
JSRV LTR and coding regions of pJS21-lacZ were confirmed
by DNA sequencing. To test if the LTR reporter construct is
specifically active in lung epithelial cell lines, the plasmid was
transfected into the murine type II pneumocyte-derived MLE-
15 cell line (Wikenheiser et al., 1993), and beta-galactosidase
activity was measured. For comparison, a lacZ reporter plasmid
driven by the highly active human cytomegalovirus (CMV)
immediate early promoter was also tested, as well as a CMV
promoter-containing plasmid that did not encode lacZ
(pcDNA3.1). As shown in Fig. 1B, pJS21-lacZ showed sig-
nificant activity in MLE-15 cells (ca. 25% the level of pCMV-
lacZ). In contrast, parallel transfections in murine NIH-3T3
fibroblasts showed very low activity of pJS21-lacZ compared to
pCMV-lacZ, indicating that the LTR is essentially inactive in
this cell line. This was consistent with our previous studies of
JSRV LTR specificity (Palmarini et al., 2000). These results
indicated that the JSRV-lacZ reporter construct was active ine founder was tested by X-gal staining of tissue sections of lung (A), spleen (B),
g) was found only in the lung, and representative cells are highlighted by arrows.
Fig. 3. Transgene expression in two different LTR-lacZ transgenic mouse lines
as shown by β-Gal assay. Lung sections from a transgenic A line F1 (A) and
from a G line F1 (B) show positive staining. Representative cells are highlighted
by arrows. Transgene expression was more frequent and generally distributed in
the G line animals.
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when assayed by transient expression in a cell line.
The LTR-lacZ gene was excised from pJS21-lacZ by
digestion with the appropriate restriction endonucleases,
purified and provided to the UCI Genetically Modified Rodent
Facility. The purified LTR-lacZ gene was microinjected into
fertilized mouse ova, which were then implanted into
pseudopregnant foster mothers. PCR screening of DNAs from
tail snips identified 11 pups (9 males and 2 females) that
contained the transgene (A–K, Table 1). These transgenic
founders were crossed with non-transgenic C57Bl6 animals,
and all eleven founders transmitted the transgene to F1 animals.
Expression of the transgene in different tissues
To test for transgene expression, transgenic F1 animals were
sacrificed and lung, spleen, liver and kidney tissues were frozen
in OTC medium, and frozen sections were prepared for assays
of transgene expression. The lung was of primary interest, in
light of the previous in vitro studies of JSRV LTR specificity in
lung epithelial cell lines, and also the fact that JSRV induces
lung cancer in sheep. The spleen was chosen because it supports
replication of many retroviruses such as murine leukemia virus
(Coffin et al., 1997). The liver and kidney do not support
replication of a number of retroviruses (e.g. murine leukemia
viruses); in the case of the liver, hepatocytes do not express
receptors for MuLV (MacLeod and Kakuda, 1996), while
kidney cells do not have division capacity (a prerequisite for
infection by simple retroviruses). On the other hand, transcrip-
tion factors such as HNF3 and C/EBP drive expression of both
liver-specific and lung-specific genes, and expression of the
JSRV LTR in MLE-15 cells has been found to be strongly
influenced by the presence of binding sites for these factors. An
in situ X-gal assay was performed on sections from each tissue
(Alam and Cook, 1990; Ausubel, 1997); lacZ-positive cells
appeared dark blue under light microscopy.
Of the 11 transgenic founders, two (A and G) yielded
transgenic F1 progeny that expressed the transgene (Table 1).
Three A line transgenic F1 animals showed transgene expression
in the lung, but not in liver, spleen and kidney (Fig. 2). This
would be consistent with the JSRV LTR driving transgene
expression in a lung-specific manner. In the first A line F1 litter,
two transgenic animals did not show transgene expression (in
addition to the three that did). This could represent segregation
of non-expressing transgenes from expressing transgenes, or
alternatively silencing of the transgene in some animals. In any
event, two A line expressing transgenic F1 animals were bred,
and F2 transgenic animals were tested. None of them showed
transgene expression in lung or other tissues. In addition, the A
line founder was re-bred, yielding more F1 transgenic animals.
Some of these F1s did show transgene expression in the lung, but
the levels of expression were reduced. Typically less than five
isolated blue stained cells were visible in an entire lung section,
in contrast to the clusters (up to 12) of intensely blue cells visible
in the F1s from the initial litter (Fig. 2). These results would be
more consistent with transgene silencing. After the F1 and F2
animals were analyzed, the A line founder was sacrificed andanalyzed. As expected, the founder showed low level transgene
expression in the lung (Table 1), but not in other tissues.
F1 transgenic animals from the G line founder showed
stronger expression than for the A line. All 8 transgenic F1
animals from the first litter showed strong transgene expression
only in the lung (Fig. 3). The G line founder was repeatedly bred
to yield ten more litters of F1 animals. The subsequent F1 litters
showed less transgene expression as compared to the first litter
(Fig. 4)— in some cases the level expression was similar to that
observed in F1 animals from the A line, and in some cases there
was no expression in the transgenic animals. Two F1 transgenic
animals from the 2nd litter were bred, and the F2 animals were
analyzed (Fig. 4). In one case, the F2 transgenic animals showed
low level expression, while in the other case no F2 transgenics
showed expression. These results also strongly support the
hypothesis that transgene silencing was occurring. Ultimately
the G line founder was sacrificed and analyzed. As expected,
this animal showed expression in the lung, although the level of
expression was in fact low (Fig. 4). This could have resulted
from tissue mosaicism, or somatic silencing of the transgene in
the lung.
Previous studies have identified DNA methylation and chro-
matin condensation (e.g. histone deacetylation) as causes of
retrovirally transduced genes (Chen and Townes, 2000). Fur-
thermore, retroviral transgenic sequences have a history of
being selectively silenced by host systems, perhaps as a defense
Fig. 4. Transgene silencing in the G line. Lung transgene expression in a partial G line pedigree in the founder, F1, and F2 generation transgenic animals is shown.
Expression in three successive F1 litters is shown, with the first breeding on the left, the second breeding in the middle, and the third breeding on the right. The degrees
of β-Gal transgene expression are indicated by shading, from most intense to least as shown in the key. Transgenic F1s from all subsequent breedings (litters 4–11, not
depicted) did not express the transgene.
402 R.M. Dakessian, H. Fan / Virology 372 (2008) 398–408mechanism against infection or tumorigenesis (Swindle and
Klug, 2002). Moreover, treatment of murine cells with the DNA
demethylating against 5-Aza-cytidine activated endogenous
MuLVs (Hoffmann et al., 1982). To test the hypothesis that
methylation-based silencing might be occurring in these JSRV
LTR-lacZ transgenics, one litter of G line F2 pups was
intraperitoneally inoculated with 5-AzaC (40 μg per animal)
twice a week for 5 weeks. Under these conditions, 5-AzaC has
been shown to eliminate genomic methylation and stimulate
transcription of silenced genes (Jaenisch et al., 1985). However
5-AzaC treatment of the JSRV-lacZ F2 transgenics did not result
in transgene expression in the lung or other tissues at the end of
the treatment period (not shown).
All other transgenic founders that did not produce transgene-
expressing F1s were sacrificed after two negative litters were
obtained. They were then analyzed for transgene expression.
One additional founder (I) was found to express the transgene at
low levels in the lung but not in other tissues (Table 1). This
founder might not have contained the expressing transgene in its
germline, or alternatively its transgene might have been subject
to extremely strong silencing.
Identification of lung epithelial cells expressing the transgene
When we initiated these experiments, we anticipated
obtaining transgenic lines that stably and consistently expressed
the LTR-lacZ transgene. This would have facilitated identifica-
tion of the lung cells expressing the transgene, the ultimate goal
of these experiments. Lung tissues could be fixed and sectioned
under optimal conditions. However, as shown above, apparent
transgene silencing was a major issue; the G line has been
maintained (currently at the F2 and F3 generations), although the
animals do not currently express the transgene. Nevertheless,
sufficient tissue was retained from animals from early F1 litters
for more detailed analyses. We studied lung tissues from animals
found to express the transgene by the initial X-gal staining.
These tissues had been frozen, since β-galactosidase assays
cannot be performed efficiently on fixed tissues. On the other
hand, identification of cell types within the lung requires higher
resolution analyses of fixed tissues sections. Therefore, frozen
lung tissues fromA andG line F1s were thawed and then fixed informalin, embedded in paraffin and sectioned. Depending on the
particular tissue sample, the degree to which the lung
architecture was preserved varied. For some samples, well-
defined alveoli were evident, while in other samples, the alveolar
structure was collapsed. Nevertheless there was sufficient
preservation to allow identification of the relevant cells and
cell types within the lung sections.
Since JSRV-induced tumors in sheep have phenotypic
markers of type II pneumocytes and/or Clara cells, we tested
if these cell types were expressing the transgene in animals
from the A and G lines. This was accomplished by three-color
immunofluorescence, using polyclonal antisera for pre-surfac-
tant protein C (SPC, specific for type II pneumocytes), CC10
(specific for Clara cells), and a MAb specific for the T7 protein
10 epitope (present in the transgene) (Rooney et al., 1994).
Visualization of SPC employed a secondary antibody con-
jugated to the Alexafluor 555 fluorophor, anti-CC10 was
visualized by a secondary antibody conjugated to Alexafluor
488, and the T7 epitope was visualized by a secondary antibody
conjugated to Alexafluor 647. Use of these fluorophors was
important because their emission spectra were well separated.
They were also advantageous because immunofluorescence at
these wavelengths did not show the high autofluorescence that
made use of other fluorophors (e.g. fluorescein) problematic.
Staining for SPC identified individual cells in the alveolar areas
of the lung (Fig. 5, panels B and F), as expected for the
distribution of type II pneumocytes. Staining for CC10
identified grouped cells lining vessels (Fig. 5, panels D and
H), as expected for Clara cells lining the bronchioles. Kim et al.
(Kim et al., 2005) have recently identified bronchiolo-alveolar
stem cells (BASCs) that have the capacity to divide and
differentiate into both type II pneumocytes and Clara cells.
They express both SPC and CC10, and are located at
bronchiolo-alveolar ductal junctions. Small numbers of cells
positive for both SPC and CC10 (and located near bronchiolo-
alveolar ductal junctions) were also detected (Fig. 5, panel K).
Fig. 5 shows three-color immunofluorescent staining of lung
sections from two G line F1 transgenics for the transgene (T7
epitope), SPC and CC10. In addition, the sections were stained
with the DNA-binding dye DAPI, which allowed visualization
of all of the cells in the section. As shown in panels B and F,
Fig. 5. Identification of transgene-expressing lung cells. (A–D) Two-color immunofluorescence of lung sections from an A line F1 transgenic animal. A) and B) show
the same field from the alveolar region, stained with DAPI to visual all nuclei (A), and with antibodies specific for SPC (green) and the T7 transgene epitope (Xpress)
(red). The actual secondary antibody for SPC was Alexafluor 555 and the secondary for Xpress was Alexafluor 647; the green and red staining shown are false color
images. Arrows indicate cells staining for both SPC and the transgene. (C) and (D) show the same field from a bronchiolar region; (C) DAPI stain;( D) double
immunofluorescence for CC10 (green) and Xpress (red). While bronchiolar cells readily stained for CC10, none stained for the transgene. (E–H) Similar analysis of a
G line F1 transgenic animal. (E and F) show the same field from the alveolar region; (E) DAPI stain, (F) anti-SPC and anti-Xpress stain. Transgene-positive SPC-
stained cells are indicated by the arrows. (G and H) show the same field from the bronchiolar region; (G) DAPI stain, (F) anti-CC10 and anti-Xpress stain. No
transgene-positive Clara cells were detected, although one X-press positive non-Clara cell was evident in the field (H, upper left). (I–K) Detection of a BASC cell in a
G line F1 transgenic animal. The same field is shown stained individually with anti-SPC (I, green false color), CC10 (J, red false color), and anti-SPC, anti-CC10 and
anti-Xpress (K). A BASC cell, identified by staining for both SPC and CC10 and by its location at the bronchiolar–alveolar duct junction is indicated by the arrow in
panel K. This cell was not positive for Xpress staining. The Alexafluor stains used allowed simultaneous detection of all three antibodies, although no Xpress-positive
BASC cells were identified.
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expressed the transgene (red stain; appearing as yellow due to
simultaneous expression). In contrast, CC10-positive cells
(panels D and H) did not show expression of the transgene.
(Note that all panels are in false color.) Thus these results
provided evidence for expression of the transgene in type II
pneumocytes, but not in Clara cells. A rare BASC cell (positive
for both SPC and CC10) is shown in panel K. This cell was not
positive for transgene expression.
To quantify the transgene expression in the different lung cell
types, multiple lung sections from the A and G line F1 animals
were analyzed by 3-color immunofluorescent staining, all of the
fluorescent cells in the sections were tabulated, and the results
are shown in Table 2. For the one A line animal, 5.5% of type II
pneumocytes (SPC+) were found to express the transgene, while
no Clara cells (CC10+) did. One BASC cell (SPC+CC10+) was
detected, and it was negative for transgene expression. Only 14 /137 (10%) of the transgene expressing cells were negative for
SPC expression, indicating that type II pneumocytes accounted
for the great majority of transgene-expressing cells. Similar
results were obtained for two G line F1 animals. As expected,
the overall level of transgene expression was higher, with
14.8% of the type II pneumocytes showing expression. Similar
to the A line, no transgene expression was detected in Clara
cells or the rare BASC cells. Taken together, these results
indicated that the JSRV LTR was active in type II pneumocytes
in these transgenic lines, while expression in Clara cells was not
detected.
While the lack of expression of the transgene in Clara cells
was statistically significantly different from the level of
expression in type II pneumocytes for both the A and G line
animals (Pb1.9×10−7 by the Fisher Exact test), the small
number of BASC cells detected in the sections described in Table
2 did not allow conclusions to be drawn. Therefore additional
Table 2
Transgene Expression in Type II Pneumocytes
SPC-positive CC10-positive Xpress Alone
SPC SPC +
Xpress
% Xpress + CC10 CC10 +
Xpress
“A" line F1 599 36 6.0% 109 0 0
743 39 5.2% 89 0 7
755 48 6.4% 104 0 7
TOTAL 2097 123 5.9% 302 0 14
“G" line F1 839 141 16.8% 160 0 9
622 121 19.5% 143 0 5
504 81 16.1% 58 0 0
TOTAL 1965 343 17.5% 361 0 14
Cumulative results of immunofluorescent staining of transgene-expressing lung
sections from A line and G line F1 animals, as illustrated in Fig. 5. Results from
three lung sections for each animal are shown. Transgene-expressing cells that
did not stain for either SPC or CC10 are also shown (Xpress alone).
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facilitate the analysis, sections were scanned only for BASC cells
(doubly positive for SPC and CC10, located at bronchiolo-
alveloar duct junctions) and the BASC cells were scored for
expression of the transgene. In total, 23 BASC cells were
identified, and none were found to express the transgene. This
level was statistically significantly different from the 15% level
of expression in type II pneumocytes (Pb0.04 by the Fisher
Exact test).
Discussion
In this report we studied the in vivo tissue and cell-type
specificity of the JSRV LTR in a transgenic mouse model. The
mice contained a transgene consisting of the JSRV LTR driving
β-galactosidase, which allowed detection of transgene expres-
sion by X-gal staining of frozen sections. The presence of a T7
gene 10 epitope in the transgene also allowed detection of
expression by immunofluorescent staining with a specific MAb.
In both the A and G line transgenic F1 animals, transgene
expression was detected in lung cells, with G line animals
showing higher levels of expression than A line animals. Thus
the results were very likely to reflect JSRV LTR specificity and
not effects of chromosomal insertion sites on the specificity of
the transgene expression.
Transgene expression was not observed in spleen, liver or
kidney, indicating that the JSRV LTR drove transgene expres-
sion in a lung-specific manner. It would have been desirable to
further assess the tissue specificity of the transgene by surveying
a wider variety of somatic tissues. However, as discussed below,
the strong transgene silencing in these lines prevented this. By
the time the extent of silencing was appreciated, F1 litters from
the original A and G founders no longer expressed the transgene,
even in the lung. The only tissues available for analysis were
archival samples from the very first or second F1 litters, and in
those cases a limited selection of tissues were harvested to
facilitate the initial screening.
Three color immunofluorescent staining with markers for
type II pneumocytes (SPC), Clara Cells (CC10) and the trans-
gene (the T7 epitope) allowed identification of the transgene-expressing cells. In both the A and G lines, type II pneumocytes
accounted for the vast majority of transgene expressing cells.
This indicated that the JSRV LTR is active in type II
pneumocytes in vivo. In a recent systematic study, the great
majority (16/17) of JSRV-induced OPA tumors in sheep
consisted predominantly of Type II pneumocytes (Platt et al.,
2002). This supports the notion that the tumor specificity of
JSRV for type II pneumocytes is strongly influenced by the
transcriptional specificity of the JSRV LTR for these cells. These
results were also consistent with our previous finding that the
type II pneumocyte-derived murine cell line MLE-15 supports
the highest level of JSRV LTR activity in transient transfection
assays.
The results also indicated that the transgene was not
detectably expressed in Clara cells, as measured by lack of co-
staining with the Clara cell marker CC10 and absence of
transgene expression in the bronchioles. This would suggest that
mature Clara cells are not targets for JSRV infection and
transformation. This was somewhat surprising since ovine OPA
tumors often show evidence for presence of Clara cells, although
in the recent study of Platt et al. (Platt et al., 2002), the
percentages of cells with morphological characteristics of Clara
cells were typically low (b10%). Only 1/17 tumors consisted of
cells with predominantly Clara cell properties. We previously
found that the JSRV LTR is active in the murine Clara cell-
derived cell line mtCC1-2, although its level of expression was
less than for the type II pneumocyte-derived MLE-15 cells
(Palmarini et al., 2000).
Another attractive explanation for the origin of OPA tumors
with mixed type II pneumocyte and Clara cell characteristics
could be that the targets for JSRV infection and transformation
are the BASC cell progenitors that can differentiate into either
Type II pneumocytes or Clara cells. However, extended analysis
of the G line transgenics did not identify any transgene-
expressing BASC cells, and the results were statistically
significant. Thus these results do not support the hypothesis
that the true targets for JSRV infection and transformation are
BASC cells. An alternative explanation could be that during
oncogenic transformation of type II pneumocytes, a minority of
the cells undergo transition to a phenotype resembling Clara
cells, including expression of CC10.
In a recent publication, Hendrickson et al. studied in vivo
infection of mice with lentiviral vectors driven by JSRV LTR,
SPC or CC10 promoter/enhancer sequences (Hendrickson et al.,
2007). They found transgene expression was observed in Type II
pneumocytes from the SPC driven lentiviral vector, and in Clara
cells from the CC10 promoted lentiviral vector. However,
expression was not detected in non-respiratory tissues following
delivery of the lentiviral vectors containing the JSRV sequences
to mice. These results were consistent with the ability of the
JSRV LTR to drive expression in lung epithelial cells, although
the JSRV chimeric LTR did not drive vector expression as
specifically as chimeric LTRs driven by enhancers from the SPC
or CC10 promoters. The somewhat broader tissue specificity of
the chimeric JSRVLTRmight have reflected interaction of JSRV
enhancer elements with other transcription motifs in the
chimeric LTR of the vector, or omission of some specificity
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(Platt et al., 2002) observed JSRV protein expression in lung
macrophages from sheep with OPA. This might have reflected
JSRVexpression in macrophages, or alternatively phagocytosis
of epithelial tumor cells.
Apparent transgene silencing was a significant technical
challenge in these experiments. This was evident as lack of (or
diminished) transgene expression in succeeding F1 litters from
both the A and G line founders, which was extensively
documented for the G line in Fig. 4. Indeed, transgene silencing
may have also been responsible for the fact that only 3/11
transgenic founders expressed the transgene, with 2/11 showing
expression in some F1 animals. Operationally, this has limited
further analysis of these transgenic lines. Stably expressing the
JSRV LTR-lacZ transgenic lines would have facilitated further
exploration of transgene expression in other tissues (e.g. mac-
rophages and other hematopoietic cells). Isolation and culture of
BASC cells from such lines would also have allowed study of
transgene expression in cells as they differentiate into mature
type II pneumocytes or Clara cells. However, these experiments
could only analyze the archival tissues harvested during the
initial screenings. In the future, it would be possible to address
some of these questions, by generating new transgenic founders
and extensively analyzing early F1 offspring, even before their
transgene expression (which requires sacrificing the animals) is
determined.
Silencing of transgenes in transgenic mice has been observed
in many situations. In particular, retroviral sequences have been
found to be subjected to silencing in a variety of contexts. For
instance, germline infection of Moloney murine leukemia virus
yielded some proviruses that expressed, but many did not
(Jaenisch et al., 1981). More recently, silencing of retroviral
vector transgenes by chromatin remodeling and formation of
repressive histone structures has been reported (Pannell et al.,
2000). Similarly, the majority of (but not all) endogenous
retroviral proviruses in many species also are not expressed,
even though they are present in high copy numbers. It has been
proposed that this silencing may reflect a host response for
limiting expression of endogenous retroviruses (Harbers et al.,
1981). Indeed, germline infection of MuLV-based retroviral
vectors results in frequent silencing, similar to endogenous
MuLV-related proviruses. On the other hand, substitution of
lentiviral LTRs onto the vectors resulted in high level
expression from the germline, indicating that MuLV (but not
lentiviral) LTR sequences are targets for gene silencing (Lois
et al., 2002). Thus it is plausible that JSRV LTR sequences
could also be subject to specific silencing in these transgenic
mice. We also observed low frequencies of expression of a
transgene expressing the JSRV env gene under control of the
cellular surfactant A (SPA) promoter (Dakessian et al., 2007).
(Both SPA and SPC are specifically expressed in type II
pneumocytes, with SPA transcription occurring later in
embryogenesis). Thus it is possible that efficiently silencing
of JSRV coding sequences also occurs in transgenic mice.
Several mechanisms have been reported in transcriptional
silencing of cellular genes, including DNA methylation, histone
deacetylation, and chromatin condensation (Wolffe and Matzke,1999; Attwood et al., 2002; Dillon, 2004). For retroviruses, in
vitro infection of cells with retroviruses or retroviral vectors
shows evidence of gene silencing, and in some cases this is
mediated (at least initially) by DNA methylation. For example,
when methylated Moloney murine leukemia virus-based
proviruses were introduced into human embryonic stem cells,
proviral association with proteins containing methyl-CpG
binding domains (including histone deacetylases) was observed
(Lorincz et al., 2001). However, incubation of infected cells in
5-AzaC results in activation of inactivated proviruses in some
but not all situations (Conklin et al., 1982; Hoeben et al., 1991).
However, treatment of G line F2 mice with 5-AzaC did not
increase transgene expression, indicating that silencing of the
JSRV LTR-lacZ transgene was not exclusively dependent on
methylation. Gaudet et al. (Gaudet et al., 2003) also studied
mice genetically lacking the major DNA methyl transferase. In
these mice, genetically transmitted M-MuLV proviruses were
not activated.
The transgene silencing observed in this experiments ap-
parently involves different or additional mechanisms than DNA
methylation. In the future, it would be interesting to test if treat-
ment with a histone de-acetylase inhibitor such as trichostatin
A (alone or in combination with 5-AzaC) can activate the
transgene from the JSRV LTR-lacZ transgenic mice or cells
derived from them, as reported for other retroviruses (Katz et al.,
2007). Treatment of mouse cells (andmice) with the halogenated
pyrimidines BrdU and IdU has been shown to induce expression
of endogenous MuLV proviruses (Lowy et al., 1971; Aaronson,
1971; Besmer et al., 1975;McCubrey et al., 1982). It is unclear if
these nucleosides are affecting DNA methylation, since meth-
ylation is predominantly at C residues; some other mechanism
might be affected. Thus it could be interesting to test the effects




pJS21-lacZ was constructed by substituting sequences from
pcDNA3.1/HisB/lacZ plasmid (Invitrogen) into the psJS21-luc
plasmid constructed previously (Palmarini et al., 2000). The
luciferase gene was replaced by the lacZ ORF from pcDNA3.1/
HisB/lacZ using established procedures (Ausubel, 1997).
pCMV-lacZ was constructed by removing the JSRV LTR
sequences in pJS21-lacZ and substituting the CMV immediately
early promoter upstream of the lacZ ORF.
Pronuclear injections
DNA injections into fertilized Balb/c X C57/Bl6J (CB6F1)
mouse ova followed by implantation into pseudopregnant foster
mothers were performed by the Genetically Modified Rodent
Facility at the University of California, Irvine. C57Bl/6J mice
were purchased from Jackson Laboratories, Inc., Bar Harbor,
ME. DNA restriction fragments for microinjection were
separated from plasmid sequences by electrophoresis on type
406 R.M. Dakessian, H. Fan / Virology 372 (2008) 398–408II agarose gels (Fisher Scientific, Houston, TX). Bands con-
taining the desired fragments were excised and the DNA was
recovered with QIAquick Gel Extraction Kit (Qiagen Inc,
Valencia CA) and purified using the GeneClean Spin Kit (Q-
Biogene, Irvine, CA).
Genotyping
Genomic DNAs frommicewere isolated from tail clippings by
incubation in proteinase K (20 mg/ml in TE Buffer, pH 8.0 at
37 °C), followed by phenol-chloroform extraction (Lin et al.,
1989). PCR detection of the transgene was performed using the
HotMaster PCRKit (Eppendorf, Hamburg,Germany)with primer
sets recognizing sequences from the JSRV Long Terminal Repeat
(GenbankAccession no. AF105220): 5′-TGGGAGCTCTTTGG-
CAAAAGCC-3′, 5′-CAGCGGATTTTTACACAATCACCGG-
3′. All primers were synthesized by Invitrogen, Carlsbad, CA.
Tissue preparations
Animals were killed and subjected to full necropsy. Tissues
were embedded in Tissue-Tek® O.C.T. compound (Fisher) and
stored at −20 °C. Samples for immunofluorescence microscopy
were thawed, fixed in 20% neutral buffered formalin (Sigma-
Aldrich, St. Louis, MO) and embedded in Paraplast X-tra tissue
embedding medium (Fisher). Sections at 8 μm thickness were
cut on a microtome and mounted on Superfrost Plus microscope
slides (Fisher).
Cell lines
MLE-15 cells (provided by J. Whitsett, Cincinnati, OH) were
grown in RPMI 1640 (Gibco BRL), 2% FBS, 0.5% ITS (Sigma),
modified with the addition of 5 mg/L transferrin, 10 mM
HEPES, 1 3 1028 M b-estradiol and 1 3 1028 M hydrocortisone.
3T3 (ATCC) were grown in DMEM (ATCC) and 10% FBS.
Both cell types were cultured at 37 °C with 5% CO2.
Reporter assays
For transient transfections, 2×105 cells were plated per well
on six-well plates (Falcon) approximately 24 h before
transfection. For each well, 300 ng of plasmid DNA (200 ng
of pcDNA3.1, pJS21-lacZ, or pCMV-lacZ) and 6 ml fugene
(Boehringer) were used as recommended by the manufacturers.
After 48 h, transfected cells were washed with PBS and lysed
with 500 ml/well of passive lysis buffer (Promega). Lumines-
cent β-Gal assays were performed on 25 μl of cleared lysate
with the Beta-Glo Assay System (Promega) and light output
was integrated over 10 s at room temperature using a Moonlight
2010 luminometer (Analytical Luminescence Laboratory).
X-gal staining
Frozen tissue were sectioned at 15 μm, mounted on Superfrost
Plus microscope slides (Fisher), and fixed in 8% glutaraldehyde.
Sections were then stained in 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) staining solution to evaluate
transgene expression as described previously (John Wiley &
Sons., 1990).
Immunofluorescence
Tissue sections on slides were deparaffinized in 100% xylene
and rehydrated in ethanol gradients (2×100%, 2×95%)
(Ausubel, 1997). For immunohistochemistry, samples were
first subjected to antigen retrieval by submersion in 0.1 M
sodium citrate buffer (pH 6.0) and microwaving for 20 min.
Sections were then incubated with rabbit polyclonal anti-SPC
(HA) antibody (1:200, Chemicon International), goat poly-
clonal anti-CC10 antibody (1:1000, Chemicon International),
and mouse monoclonal Anti-Xpress (Invitrogen) in 5% donkey
serum overnight at 4 °C. After washing, the samples were in-
cubated overnight at 4 °C in 5% donkey serum with the
following antibodies: donkey anti-goat IgG conjugated to
Alexa-Fluor 488 (1:200), donkey anti-rabbit IgG conjugated
to Alexa-Flour 555 (1:200), and donkey anti-mouse IgG
conjugated to Alexa-Flour 647 (1:200). Tissues were visualized
with fluorescent microscopy at 200× magnification on a Zeiss
LSM510-META NLO (multi-photon) confocal microscope.
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